These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 25994247)

  • 1. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015; 15(7):847-58. PubMed ID: 25994247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
    Abdel-Rahman O; ElHalawani H; Essam-Eldin S
    Expert Opin Drug Saf; 2016 Jan; 15(1):5-20. PubMed ID: 26513339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
    Lo Muzio L; Arena C; Troiano G; Villa A
    Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2014 Dec; 14(12):1529-36. PubMed ID: 25159115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
    Rugo HS; Hortobagyi GN; Yao J; Pavel M; Ravaud A; Franz D; Ringeisen F; Gallo J; Rouyrre N; Anak O; Motzer R
    Ann Oncol; 2016 Mar; 27(3):519-25. PubMed ID: 26759276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
    Peng L; Zhou Y; Ye X; Zhao Q
    Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
    Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
    Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(1):79-90. PubMed ID: 25572784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
    Shameem R; Lacouture M; Wu S
    Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
    Sivendran S; Agarwal N; Gartrell B; Ying J; Boucher KM; Choueiri TK; Sonpavde G; Oh WK; Galsky MD
    Cancer Treat Rev; 2014 Feb; 40(1):190-6. PubMed ID: 23684373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H; Ahmed H; Ellithy M
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1433-45. PubMed ID: 26365425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
    Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
    PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
    Gomez-Fernandez C; Garden BC; Wu S; Feldman DR; Lacouture ME
    Eur J Cancer; 2012 Feb; 48(3):340-6. PubMed ID: 22206873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
    Garcia CA; Wu S
    Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.